Work

PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).

Year: 2021

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2021.39.6_suppl.tps366

Authors: Tian Zhang, Karla V. Ballman, Atish Dipankar Choudhury, Ronald C. Chen, Colleen Watt, Yujia Wen, Ardaman Shergill, Tyler J. Zemla, Hamid Emamekhoo, Ulka N. Vaishampayan, Michael J. Morris, Daniel J. George, Toni K. Choueiri

Institutions: Duke University, Duke Cancer Institute, Weill Cornell Medicine, Dana-Farber Cancer Institute, University of Kansas, Alliance for Clinical Trials in Oncology, University of Chicago, University of Illinois Chicago, Mayo Clinic, University of Wisconsin–Madison, University of Michigan, Memorial Sloan Kettering Cancer Center, Harvard University, Dana-Farber/Harvard Cancer Center

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: National Institutes of Health

OpenAlex ID: W4249997260

Cites:

Cited by: 26

Related to: 10